Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00004060 · ClinicalTrials.gov registry record · Phase 2
Chemotherapy in Treating Patients With Recurrent, Metastatic, or Unresectable Ovarian, Fallopian Tube, or Peritoneal Cancer
A Phase 2 study, sponsored by Daiichi Sankyo.
- Completed
- Registry status
- Phase 2
- Development phase
NCT00004060 is a Phase 2 study that has completed, run by Daiichi Sankyo.
The verdict
NCT00004060, a Phase 2 study, has completed, sponsored by Daiichi Sankyo.
- COMPLETED
- Registry status
- Phase 2
- Development phase
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of DX-8951f in treating patients who have recurrent, metastatic, or unresectable ovarian, fallopian tube, or peritoneal cancer.
Interventions
- DRUG exatecan mesylate
Trial Details
| Field | Value |
|---|---|
| Start Date | 1999-07 |
| Est. Completion | 2000-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00004060
The ClinicalTrials.gov registry entry for NCT00004060 describes a study currently listed as completed, categorized as Phase 2. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Daiichi Sankyo, which has 236 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which exatecan mesylate is the first listed.
NCT00004060 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00004060 about?
NCT00004060 is a clinical study titled "Chemotherapy in Treating Patients With Recurrent, Metastatic, or Unresectable Ovarian, Fallopian Tube, or Peritoneal Cancer". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of DX-8951f in treating patients who have recurrent, metastatic, or unresectable ovarian, fallopian tube, or peritoneal cancer.
What is the current status of trial NCT00004060?
This trial is currently completed. It is a Phase 2 study. The study started on 1999-07. Estimated completion is 2000-09.
What interventions are being tested in trial NCT00004060?
The interventions under investigation include: exatecan mesylate (DRUG).
Who is sponsoring clinical trial NCT00004060?
This trial is sponsored by Daiichi Sankyo, which has 236 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.